The Pharma Data

DECEMBER 18, 2020

FDA Approves Orgovyx (relugolix) as the First Oral Gonadotropin-Releasing Hormone (GnRH) Receptor Antagonist for Advanced Prostate Cancer. Food and Drug Administration (FDA) has approved Orgovyx (relugolix) for the treatment of adult patients with advanced prostate cancer. “I BASEL, Switzerland, Dec.

FDA Approval 52

FDA Approval FDA Science Therapies 52

Drug Discovery World

MAY 29, 2024

Marc Hummersone, Senior Director of Research and Development (R&D) at Astrea Bioseparations, shares insight on the challenges and opportunities in cell and gene therapy (CGT) with DDW’s Megan Thomas. Looking over the last five to eight years, he reflects on the handful of FDA approvals and CGTs that really work well.

Therapies 273

Therapies Molecular Biology DNA Immune Response 273

The Pharma Data

JANUARY 20, 2021

Food and Drug Administration (FDA) has accepted the company’s supplemental New Drug Application (sNDA) and granted Priority Review for Esbriet ® (pirfenidone) for the treatment of unclassifiable interstitial lung disease (UILD). The FDA is expected to make a decision on approval by May 2021. Since its U.S. About Esbriet.

FDA 52

FDA Disease Doctors Treatment 52

The Pharma Data

NOVEMBER 15, 2020

However, doctors are continuing to prescribe the drugs “off-label” for kids with conditions like attention deficit hyperactivity disorder (ADHD), anxiety, depression and conduct disorders, the research found. SUNDAY, Nov. The medications don’t have the safety and effectiveness data needed, nor do they have U.S.

FDA Approval 52

FDA Approval Doctors Treatment Therapies 52

Drug Discovery World

APRIL 14, 2023

He is being recognised for his revolutionary contributions to developing the first gene-edited cell-based therapy for cancer that involves the genetic re-engineering of a patient’s own T cells to combat their disease, and for demonstrating that adoptive T-cell therapy can induce remission and in some cases cure patients with advanced cancer.

Clinical Trials 130

Clinical Trials Research Science Clinical Research 130

The Pharma Data

SEPTEMBER 10, 2021

More than 20 abstracts across disease states, including Parkinson’s disease, spasticity and cervical dystonia, will be presented. “Our research presented at MDS 2021 builds upon our expertise in neuroscience and reinforces our mission to advance the standards of care for people living with these debilitating diseases.”

Doctors 52

Doctors Clinical Trials Disease Treatment 52

PLOS: DNA Science

JUNE 1, 2023

The newest FDA-approved gene therapy treats the severe, skin-peeling condition dystrophic epidermolysis bullosa (DEB). The gene treatment has been a long time coming, but it differs from the handful of other approved gene therapies: it isn’t a one-and-done.

FDA Approval 52

FDA Approval Therapies FDA Disease 52

The Pharma Data

JULY 21, 2021

mg, 5 mg, and 10 mg) is indicated for the treatment of symptomatic chronic heart failure in adult patients with reduced ejection fraction who are stabilized after a recent decompensation event requiring intravenous (IV) therapy. Bayer also issued a news release earlier today announcing the EC approval. In the EU, VERQUVO (2.5

Treatment 52

Treatment Production Hospitals FDA Approval 52

The Pharma Data

APRIL 1, 2021

“These data show upadacitinib’s potential to improve clinical and radiographic outcomes for people with psoriatic arthritis, a complex and progressive autoimmune disease,” said Thomas Hudson , MD, senior vice president, research and development, chief scientific officer, AbbVie. at week 12. About RINVOQ (upadacitinib).

Doctors 52

Doctors Treatment Therapies FDA 52

The Pharma Data

MARCH 16, 2021

1,2 TREMFYA is the first and only IL-23 inhibitor therapy approved in the U.S. PsA can be a chronically painful and debilitating disease, and many PsA patients are still searching for enduring relief of their symptoms,” said Philip J. Vice President, Rheumatology Disease Area Leader, Janssen Research & Development, LLC.

Treatment 52

Treatment Pharmacokinetics Disease Pharmaceutical Companies 52

Codon

JULY 14, 2024

While this departs from the reductionist, single-component therapies that have dominated transfusion medicine since World War II, emerging data underscores that whole blood transfusions—blood with all its parts—yield better outcomes following severe blood loss than transfusions involving discrete blood components. Always free.

Production 133

Production Clinical Trials Trials Therapies 133

The Pharma Data

SEPTEMBER 8, 2021

. “We continue to conduct research that seeks to provide additional insights into the safety, efficacy and clinical utility of our approved and investigational migraine therapies,” said Michael Gold , M.D., Related Peptide Monoclonal Antibody Therapy Added to OnabotulinumtoxinA Treatment. ePoster (on-demand only).

Doctors 52

Doctors Treatment Trials Clinical Trials 52

The Pharma Data

JUNE 26, 2021

If approved, XARELTO ® will be the first and only oral Factor Xa inhibitor indicated in the U.S. There are currently no FDA-approved anticoagulation therapies for pediatric patients with congenital heart disease who have undergone the Fontan procedure, a surgical procedure that redirects blood flow from the lower body to the lungs.

Doctors 52

Doctors Hospitals Clinical Trials Treatment 52

Agency IQ

SEPTEMBER 15, 2023

Until recently, the FDA relied on a monograph process through which firms could bring OTC drugs to market without FDA approval so long as it adhered to pre-set terms under the monograph. CHPA considered the original studies to be sound and instead found issues with the newer studies.

Science 40

Science FDA Clinical Trials Pharmacy 40

Broad Institute

OCTOBER 11, 2023

He also read everything he could about her disease, including emerging evidence that suggested that the immune system could recognize and kill Merkel cell carcinoma. His mother had a presentation of the disease that suggested her immune system was already on the job.

Research 137

Research Immune Response Clinical Trials Cell Biology 137

The Pharma Data

NOVEMBER 4, 2020

Previously they had recommended use of VASCEPA for treating patients with established cardiovascular disease. Amarin is optimistic that the worst period of impact from COVID-19 on the levels of patients seeking ordinary course doctor visits and lab tests may be behind it. Thero, president and chief executive officer. “We

Production 40

Production FDA Trials Licensing 40

Drug Target Review

AUGUST 3, 2023

Clinical trials are now underway for various genetic subtypes of both rare and common diseases, on the understanding that medications utilising genetic biomarkers have a significantly higher chance of success. There are clinical trials underway for genetic subtypes of rare and common diseases.

DNA 52

DNA Clinical Trials Trials FDA Approval 52

The Pharma Data

OCTOBER 25, 2020

Real-world effectiveness data on Oxbryta ® (voxelotor) in the treatment of sickle cell disease featured as oral presentation. Two abstracts have been accepted for presentation, including real-world effectiveness data of Oxbryta ® (voxelotor) tablets in the treatment of sickle cell disease (SCD). FDA approval. 26-31, 2020.

Treatment 52

Treatment Disease FDA FDA Approval 52

The Pharma Data

JUNE 28, 2021

If approved, Xarelto will be the only oral Factor Xa Inhibitor indicated in the U.S. Current guidelines are limited and recommend treating pediatric patients with or at risk for reoccurrence of blood clots with standard anticoagulation therapy which requires injections, dietary restrictions, and regular laboratory monitoring.

FDA 52

FDA Clinical Trials Treatment Therapies 52

The Pharma Data

JANUARY 4, 2021

.–( BUSINESS WIRE )– Genentech , a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), today announced that tiragolumab, a novel cancer immunotherapy designed to bind to TIGIT, has been granted Breakthrough Therapy Designation (BTD) by the U.S. This marks the 37th BTD for Genentech’s portfolio of medicines.

FDA 52

FDA Therapies Immune Response Treatment 52

The Pharma Data

JUNE 18, 2021

Undetectable minimal residual disease (uMRD) was achieved in 77% of patients in peripheral blood and 60% of patients in bone marrow. 2,3 CLL is predominately a disease of the elderly, with a median age at diagnosis of 70 years and is more common among men than women. vice president and global head of oncology development, AbbVie.

Treatment 40

Treatment FDA FDA Approval Therapies 40

The Pharma Data

MAY 13, 2021

WITHOUT doctors, physical therapists or chiropractors. Our Unique Solution Has Been Featured All Over The Media, From Hallmark, The Doctors, Atlanta Live & Arizona Midday…. I Have A Doctorate In Pharmacy, But Everything I Learned About Pain Relief In Pharmacy School Is Dead Wrong! And then got my Doctor of Pharmacy (Pharm.

Pharmacy 52

Pharmacy Doctors Production Therapies 52

The Pharma Data

JUNE 18, 2021

The study met its primary endpoint of superior progression-free survival (PFS) as assessed by an independent review committee (IRC) with a HR 0.216 (95% CI, 0.131-0.357; p < 0.0001), demonstrating a reduction in the risk of disease progression or death for I+V of approximately 78% compared to C+O. . About the GLOW Study.

Treatment 52

Treatment Therapies FDA FDA Approval 52

The Pharma Data

JANUARY 26, 2021

percent) in patients taking therapy and 36 events (7.0 Bamlanivimab and etesevimab together also demonstrated statistically significant improvements on all key secondary endpoints, providing strong evidence that the therapy reduced viral load and accelerated symptom resolution. It remains under review by the FDA.

Hospitals 52

Hospitals Treatment Long-Term Care Facilities Trials 52

The Pharma Data

JUNE 18, 2021

. “These data add to the overall body of evidence that patients treated with ibrutinib can achieve extended progression-free survival and overall survival when used as a first-line therapy,” said Paul M. Single-agent ibrutinib was the most common treatment across line of therapy at enrollment. Barr , M.D., IMBRUVICA ®.

FDA Approval 40

FDA Approval Treatment FDA Therapies 40

The Pharma Data

AUGUST 9, 2021

. “We know many people living with psoriasis are looking for flexibility in how they manage their disease,” said Patrick Horber, President, U.S. SKYRIZI is indicated for the treatment of moderate to severe plaque psoriasis in adults who are candidates for systemic therapy or phototherapy. Immunology, AbbVie.

Vaccine 52

Vaccine Treatment FDA FDA Approval 52

The Pharma Data

MAY 4, 2021

Rare Disease. down 21%, driven by a negative impact from the COVID-19 pandemic resulting in a decline in patient visits to doctors for preventative health purposes, as well as the loss of patent protection in the U.S. Panzyga is the only intravenous immunoglobulin (IVIg) with two FDA-approved maintenance dosing options for CIDP.

Vaccine 40

Vaccine Production FDA Clinical Trials 40

The Pharma Data

NOVEMBER 23, 2020

23, 2020 – Americans were greeted with possible advances against coronavirus as Thanksgiving week began: A third vaccine candidate shows good results in shielding recipients against the virus, and an antibody therapy used by President Donald Trump against COVID-19 got emergency use approval by the U.S. MONDAY, Nov. Meanwhile, U.S.

FDA Approval 52

FDA Approval Vaccine FDA Treatment 52